Manoj Mishra from Grant Thornton Bharat highlights a complex situation for Indian pharmaceuticals. Companies making branded drugs for the U.S. may struggle, while local generic producers might benefit from rising demand for affordable alternatives. Interestingly, despite this potential for growth, share prices of major Indian pharma firms took a hit recently. The Nifty Pharma index dropped over 2%, with Sun Pharma and Dr. Reddy’s Laboratories seeing declines of 2.9% and 1.3%, respectively.
Analysts suggest this market reaction stems from uncertainty around former President Trump’s policies. His threats of tariffs up to 200% on pharmaceutical imports have caused unease, especially since generic drugs have not yet been affected. The looming possibility of new tariffs remains a cloud over the industry.
On a positive note, Indian pharma exports to the U.S. have surged by over 17% in the 2024-25 period, despite stricter regulations. The U.S. FDA has increased surprise inspections of foreign facilities after finding compliance issues, particularly in Indian and Chinese plants. This means higher compliance costs and the risk of supply disruptions for many companies.
A report from Crisil suggests that cutting the Goods and Services Tax (GST) on life-saving and cancer treatments could benefit larger, organized manufacturers, steering demand away from smaller competitors.
To navigate these challenges, companies are diversifying their markets and focusing on specialty products. This strategic shift could help them maintain stronger pricing power and reduce competition. Improving efficiency and productivity will also be vital for sustaining profitability if new tariffs are implemented.
The current landscape reflects broader trends in the global pharmaceutical industry, influenced by regulatory changes and market demands. Keeping an eye on these developments will be essential for understanding the future of pharma in India and beyond.
For more on the impact of tariffs and regulations on the pharma industry, you can refer to the FDA’s recent reports.
Source link
Trump tariff,Indian pharma exports
